Farms.com Home   Ag Industry News

Saputo to Close Four Plants in Canada, U.S.</

Montreal-based Canadian dairy giant Saputo will close four of its plants in Canada and in the United States, citing efficiency reasons.

The company said that two of its plants in Alberta Canada and two U.S plants in Wisconsin and Maryland will close.

“Over the recent years, Saputo has maintained efforts to pursue additional efficiencies and decrease costs while strengthening its market presence,” the company said in a release.

Saputo says that production at the plants will be combined into its other facilities. The company said that the cost of upgrading the four facilities was too high. Closing the plants will save the company about $4.8 million a year.

The first round of closures will begin May 2014 and the last closure is scheduled to occur in December 2015. There will be approximately 180 employees impacted be the closures of the four plants.

Saputo is one of the top 10 dairy processors in the world and is the largest in Canada.
 


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.